The 6 analysts offering 12-month price forecasts for Adaptimmune Therapeutics PLC have a median target of 6.00, with a high estimate of 9.00 and a low estimate of 2.00. The median estimate represents a +263.64% increase from the last price of 1.65.
The current consensus among 8 polled investment analysts is to Hold stock in Adaptimmune Therapeutics PLC. This rating has held steady since August, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.29
Reporting Date Aug 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.